TY - JOUR
T1 - Adjunctive bright light therapy for bipolar depression
T2 - A randomized double-blind placebo-controlled trial
AU - Sit, Dorothy K.
AU - McGowan, James
AU - Wiltrout, Christopher
AU - Diler, Rasim Somer
AU - Dills, John
AU - Luther, James
AU - Yang, Amy
AU - Ciolino, Jody D.
AU - Seltman, Howard
AU - Wisniewski, Stephen R.
AU - Terman, Michael
AU - Wisner, Katherine L.
N1 - Funding Information:
From the Department of Psychiatry and Behavioral Sciences and the Department of Preventive Medicine–Biostatistics Division, Feinberg School of Medicine, Northwestern University, Chicago; the Department of Psychiatry, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh; the Epidemiological Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh; the Department of Statistics, Carnegie Mellon University, Pittsburgh; and the Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York. Address correspondence to Dr. Sit (dorothy.sit@northwestern.edu). Supported by NIH Career Development Award K23 MH082114 to Dr. Sit; the Brain and Behavioral Research Foundation; and a NARSAD 2013 Young Investigator Award to Dr. Sit. Dr. Sit also received donations of light boxes from Uplift Technologies, Inc., for use in the study.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Objective: Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Buildingon promising pilot data, the authors conduct ed a6-weekr and omizeddouble-blindplacebo-controlledtrial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level, and rate of mood polarity switch, as well as to explore sleep quality. Method: The study enrolled depressed adults with bipolar I or II disorder who were receiving stable dosages of antimanic medication (excluding patients with hypomania ormania, mixed symptoms, or rapid cycling). Patientswere randomly assigned to treatment with either 7,000-lux bright white light or 50-lux dim red placebo light (N=23 for each group). Symptoms were assessed weekly with the Structured Interview Guide for the Hamilton Depression Scale With Atypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburgh Sleep Quality Index. Remission was defined as having a SIGH-ADS score of 8 or less. Results: At baseline, both groups had moderate depression and no hypomanic or manic symptoms. Compared with the placebo light group, the group treated with bright white light experienced a significantly higher remission rate (68.2% comparedwith 22.2%; adjusted odds ratio=12.6) at weeks 4-6 and significantly lower depression scores (9.2 [SD=6.6] compared with14.9 [SD=9.2]; adjustedb=-5.91) at the endpoint visit.No mood polarity switcheswere observed. Sleep quality improved in both groups and did not differ significantly between them. Conclusions: The data from this study provide robust evidence that supports the efficacy of midday bright light therapy for bipolar depression.
AB - Objective: Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Buildingon promising pilot data, the authors conduct ed a6-weekr and omizeddouble-blindplacebo-controlledtrial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level, and rate of mood polarity switch, as well as to explore sleep quality. Method: The study enrolled depressed adults with bipolar I or II disorder who were receiving stable dosages of antimanic medication (excluding patients with hypomania ormania, mixed symptoms, or rapid cycling). Patientswere randomly assigned to treatment with either 7,000-lux bright white light or 50-lux dim red placebo light (N=23 for each group). Symptoms were assessed weekly with the Structured Interview Guide for the Hamilton Depression Scale With Atypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburgh Sleep Quality Index. Remission was defined as having a SIGH-ADS score of 8 or less. Results: At baseline, both groups had moderate depression and no hypomanic or manic symptoms. Compared with the placebo light group, the group treated with bright white light experienced a significantly higher remission rate (68.2% comparedwith 22.2%; adjusted odds ratio=12.6) at weeks 4-6 and significantly lower depression scores (9.2 [SD=6.6] compared with14.9 [SD=9.2]; adjustedb=-5.91) at the endpoint visit.No mood polarity switcheswere observed. Sleep quality improved in both groups and did not differ significantly between them. Conclusions: The data from this study provide robust evidence that supports the efficacy of midday bright light therapy for bipolar depression.
UR - http://www.scopus.com/inward/record.url?scp=85041647622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041647622&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2017.16101200
DO - 10.1176/appi.ajp.2017.16101200
M3 - Article
C2 - 28969438
AN - SCOPUS:85041647622
VL - 175
SP - 131
EP - 139
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
SN - 0002-953X
IS - 2
ER -